Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SSB Expands PAT Software Portfolio

Published: Wednesday, December 19, 2012
Last Updated: Wednesday, December 19, 2012
Bookmark and Share
Chemometrics software for Design of Experiments (DoE) and multivariate data analysis.

Sartorius Stedim Biotech (SSB) has entered into a global sales partnership with Umetrics AB, a Swedish software manufacturer.

Umetrics is a highly specialized, leading provider of chemometrics software worldwide for modeling and optimizing biopharmaceutical development and manufacturing processes.

The cooperation agreement provides that SSB will assume global marketing and distribution of the complete Umetrics portfolio for the pharmaceutical and biopharmaceutical industries.

SSB will integrate Umetrics software programs as private label products into its own bioprocess portfolio and market these as stand-alone solutions under both brands under a dual branding arrangement.

Stefan Schlack, Senior Vice President of Marketing at SSB commented: “These software solutions will help our customers to better understand their cell culture processes and to identify potential for optimization and robust process control – an ideal addition to our bioprocess portfolio.”

The major areas of application for these software systems are critical process steps, such as cell culture processes or specific purification steps in the biopharmaceutical industry.

Multivariate data analysis (MVA) enables all process parameters to be added in batch trajectories, among other things, so that process variations and their causes can be displayed transparently in real time.

DoE software (Design of Experiments) permits these critical process parameters to be efficiently identified and quantified and development cycles to be considerably shortened.

Umetrics stands to benefit from the global sales structures of SSB. “With SSB, we can gain access to substantially more customers thanks to its international reach and solid market standing in the biopharma sector. SSB’s integrated solutions for the complete biopharmaceutical process clearly create added value for our customers. I anticipate that this will considerably boost the biopharmaceutical industry’s interest in and usage of our products,” says Lars Lindstorm, General Manager of Umetrics.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Miriam Monge to Join Sartorius Stedim Biotech
Company appoints Miriam Monge as director of marketing for integrated solutions.
Wednesday, August 27, 2014
Sartorius Stedim Announces Offer to Acquire TAP Biosystems
Sartorius Stedim Biotech to further expand its portfolio of single-use fermentors.
Tuesday, October 08, 2013
Sartorius Appoints Senior Vice President
Appointment of Stefan Schlack as Senior Vice President of marketing.
Thursday, October 25, 2012
SSB and Bosch Announce Global Collaboration
Agreement covers the mutual design and development of single-use filling solutions.
Thursday, June 21, 2012
SSB and Refine Technology Announce Cooperation
Development of a robust, easy-to-use platform for high-density cell cultivation.
Tuesday, January 24, 2012
SSB and G-Con Manufacturing Announce Global Collaboration
Collaboration will support faster and more flexible facility construction and shortened time to market.
Thursday, January 19, 2012
Sartorius Stedim Biotech and GE Healthcare Life Sciences Sign Cross-Licensing Agreement
Agreement covers intellectual property relating to biopharmaceutical manufacturing technologies.
Monday, September 12, 2011
SSB and Südpack Medica AG Sign Exclusive Cooperation Agreement
Südpack and SSB cooperate in the manufacture of plastic film.
Friday, June 17, 2011
Sartorius Stedim Biotech and RAUMEDIC Sign Partnership Agreement
SSB’s product portfolio to be extended by tubing and polymer components.
Friday, May 20, 2011
Scientific News
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
Study Reveals New Method to Develop More Efficient Drugs
A new study suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!